浙江临床医学
浙江臨床醫學
절강림상의학
ZHEJIANG CLINICAL MEDICAL JOURNAL
2014年
3期
362-364
,共3页
鼻咽癌%EBV抗原抗体%CD44
鼻嚥癌%EBV抗原抗體%CD44
비인암%EBV항원항체%CD44
Nasopharyngeal carcinoma(NPC) Epstein-Barr%Virus-related antibodies%CD44
目的:比较鼻咽癌(NPC)患者治疗前后血清EBV抗原抗体及CD44变化水平,为临床疗效判断及预测预后提供理论依据及客观指标。方法2008年9月至2009年10月初治鼻咽癌Ⅱ-Ⅳ期患者99例,治疗前检测外周血EB病毒衣壳抗原抗体(EBV-VCA-IgA)、早期抗原抗体(EBV-EA-IgA)及CD44水平,放疗结束时再次检测上述指标。结果99例鼻咽癌患者治疗前、后血清中EBV-VCA-IgA表达水平差异有统计学意义(P=0.005),EBV-EA-IgA差异无统计学意义(P=0.162)。治疗前、后血清中CD44分别为(76.77±10.08)、(73.23±12.55),P=0.002,差异有统计学意义。Ⅱ、Ⅲ、Ⅳ期患者治疗前血清CD44分别为(83.12±3.00)、(78.11±10.39)、(74.35±9.96),P=0.035,差异有统计学意义。结论与EBV-EA-IgA相比,EBV-VCA-IgA用于鼻咽癌疗效判断及监测病情可能更为灵敏和准确。CD44的高表达可能与鼻咽癌分期相关,早期鼻咽癌具有较强的转移潜力。
目的:比較鼻嚥癌(NPC)患者治療前後血清EBV抗原抗體及CD44變化水平,為臨床療效判斷及預測預後提供理論依據及客觀指標。方法2008年9月至2009年10月初治鼻嚥癌Ⅱ-Ⅳ期患者99例,治療前檢測外週血EB病毒衣殼抗原抗體(EBV-VCA-IgA)、早期抗原抗體(EBV-EA-IgA)及CD44水平,放療結束時再次檢測上述指標。結果99例鼻嚥癌患者治療前、後血清中EBV-VCA-IgA錶達水平差異有統計學意義(P=0.005),EBV-EA-IgA差異無統計學意義(P=0.162)。治療前、後血清中CD44分彆為(76.77±10.08)、(73.23±12.55),P=0.002,差異有統計學意義。Ⅱ、Ⅲ、Ⅳ期患者治療前血清CD44分彆為(83.12±3.00)、(78.11±10.39)、(74.35±9.96),P=0.035,差異有統計學意義。結論與EBV-EA-IgA相比,EBV-VCA-IgA用于鼻嚥癌療效判斷及鑑測病情可能更為靈敏和準確。CD44的高錶達可能與鼻嚥癌分期相關,早期鼻嚥癌具有較彊的轉移潛力。
목적:비교비인암(NPC)환자치료전후혈청EBV항원항체급CD44변화수평,위림상료효판단급예측예후제공이론의거급객관지표。방법2008년9월지2009년10월초치비인암Ⅱ-Ⅳ기환자99례,치료전검측외주혈EB병독의각항원항체(EBV-VCA-IgA)、조기항원항체(EBV-EA-IgA)급CD44수평,방료결속시재차검측상술지표。결과99례비인암환자치료전、후혈청중EBV-VCA-IgA표체수평차이유통계학의의(P=0.005),EBV-EA-IgA차이무통계학의의(P=0.162)。치료전、후혈청중CD44분별위(76.77±10.08)、(73.23±12.55),P=0.002,차이유통계학의의。Ⅱ、Ⅲ、Ⅳ기환자치료전혈청CD44분별위(83.12±3.00)、(78.11±10.39)、(74.35±9.96),P=0.035,차이유통계학의의。결론여EBV-EA-IgA상비,EBV-VCA-IgA용우비인암료효판단급감측병정가능경위령민화준학。CD44적고표체가능여비인암분기상관,조기비인암구유교강적전이잠력。
Purpose To evaluate the clinical significance of quantitative analysis of EBV related antibody and CD44 before and after the radiotherapy in plasma of NPC patients. Methods 99 NPC patients with preliminary diagnosis in Zhejiang Tumor Hospital form 2008 September to 2009 October were rescuited, levels of EBV-VCA-IgA,EBV-EA-IgA and CD44 before and after radiotherapy were evaluated. Result The level of serum EBV-VCA-IgA before and after radiotherapy showed a significant difference(P=0.001),but the level of serum EBV-EA-IgA showed no difference(P=0.192).Respectively,serum CD44 before and after radiotherapy were(76.77±10.08), (73.23±12.55)(P=0.002),the difference was significant.Before radiotherapy,the difference of CD44 inⅡ、Ⅲ、Ⅳstage group were significant(83.12±3.00)、(78.11±10.39)、(74.35±9.96),P=0.035). Conclusion Compared with EBV-EA-IgA,EBV-VCA-IgA was more sensitive and effective in curative effect monitoring.The high expression of CD44 may be related to the stage of NPC,the early stage of nasopharyngeal carcinoma has more power in metastasis potential.